大肠癌患者化疗前后血清可溶性Apo-1/Fas水平变化及其临床意义

Serum Soluble Apo-1/Fas Changes in Patients with Colorectal Carcinoma Undergone Chemotherapy

目的 探讨可溶性Apo 1/Fas(sApo 1/Fas)在大肠癌患者化疗前后血清中的水平及其临床价值。 方法 采用酶联免疫吸附试验法 (ELISA )对 5 5例大肠癌患者化疗前后血清sApo 1/Fas水平进行测定 ,并同时检测 3 0例正常人血清sApo 1/Fas水平作为对照。结果 大肠癌患者血清sApo 1/Fas水平明显高于正常对照组 (P <0 .0 5 ) ,血清sApo 1/Fas水平与临床分期有关、与大肠癌患者性别、年龄、细胞分化程度无关 ;DukesD期大肠癌患者血清sApo 1/Fas水平明显高于其它各期 (P <0 .0 1) ,DukesC期明显高于DukesB及DukesA期 (P <0 .0 1) ,DukesB期与DukesA期比较无显著性差异 (P >0 .0 5 ) ;分化程度较好 (高分化腺癌及中分化腺癌 )大肠癌患者血清sApo 1/Fas水平 ,与分化程度较差 (低分化腺癌及黏液腺癌 )大肠癌患者比较无显著性差异 (P >0 .0 5 ) ;化疗后有效 (完全缓解和部分缓解 )患者血清sApo 1/Fas水平明显低于化疗前 (P <0 .0 5 )。 结论 血清sApo 1/Fas的检测对探讨大肠癌的发生机理、病情判断及指导化疗有一定价值。

Objective To investigate the changes of Soluble Apo 1/Fas(sApo 1/Fas) level in patients with colorectal carcinoma before and after chemotherapy,and its clinical implication.Methods The level of sApo 1/Fas was measured by enzyme linked immunosorbent assays(ELISA) in 55 cases of colorectal carcinoma before and after chemotherapy,as compared with 30 case of normal control subject.Results The level of sApo 1/Fas was elevated in all subgroups of patients with colorectal carcinoma compared to the controls( P <0.05),sApo 1/Fas was correlated with clinical stage,and not with sex?age and histological grade;the sApo 1/Fas level in stage Dukes D was higher in comparison with stage Dukes C?Dukes B and Dukes A( P <0.01),and in stage Dukes C it was higher than in stage Dukes B and Dukes A( P <0.01);but no significant difference was detected between stage Dukes B and Dukes A( P >0.05),there was no difference between well differentiated,moderately differentiated adenocarcinoma and poorly differentiated adenocarcinoma,mucoid carcinoma( P >0.05).That the sApo 1/Fas levels were remarkably reduced in complete remission or partial remission patients( P <0.05) after chemotherapy.Conclusion Determination of sApo 1/Fas may be useful in the study of colorectal carcinoma development mechanism,judgement of patient′s,condition and guide to chemotherapy.